MAR 20, 2014 01:00 PM PDT

The role of high throughput sequencing in the research and diagnosis of neurodegenerative disorders

Presented At Neuroscience
Speakers
  • Director of Next-Gen Sequencing Laboratory Laboratory of Personalized Genomic Medicine, Associate Professor, Columbia University
    Biography
      Peter L. Nagy is a biochemist and a physician, board certified in anatomic and molecular genetic pathology.
      <br />
      <br />Dr. Nagy's research focuses on the role of transcriptional processing in the pathogenesis of neurodegenerative disorders. He developed S. pombe and M. musculus models for Ataxia-Oculomotor-Apraxia type 2 (AOA2) caused by mutations in the human ortholog of the yeast RNA helicase Sen1, Senataxin (SETX). Using these models they are working to define the pathomechanism of SETX mediated neurodegenerative disorders. They are also investigating the pathogenesis of ALS caused by C9orf72 expansions and search for novel ALS causing or modifying genetic variants.&nbsp;
      In Dr. Nagy's research, he combines the tools of classical biochemistry and genetics with genomics, most importantly next-gen sequencing for mutation discovery, transcriptome analysis and the identification of novel protein RNA interactions.
      <br />
      <br />His clinical interest is the development and use of genome-scale sequencing assays in the clinical diagnosis of constitutional disorders and cancer such as :
      <br />&nbsp;&nbsp;&nbsp; * Mitochondrial Genome Sequencing Test
      <br />&nbsp;&nbsp;&nbsp; * Columbia Combined Genetic Panel (1300 genes most commonly associated with genetic disorders)
      <br />&nbsp;&nbsp;&nbsp; * Whole Exome Sequencing Tests for Constitutional Disorders and Cancer.
      <br />
      <br />

    Abstract:

    Using high throughput next-generation sequencing to simultaneously search large number of genes for pathogenic mutations has numerous advantages. It decreases the pressure to narrow the differential diagnosis for diseases with overlapping phenotypes, can identify entirely new causative private mutations when no good candidate genes are available, and shorten the patients diagnostic odyssey. The Laboratory of Personalized Genomic Medicine at Columbia University started offering mitochondrial genome, partial and whole exome sequencing for clinical diagnostic purposes in January 2013. In my talk I will highlight the effectiveness of next-gen sequencing in diagnosing neurological and neurodegenerative conditions. Furthermore I will discuss the use of next-gen sequencing technologies to evaluate transcriptional and translational changes that might define these conditions in cell culture and animal model systems. Finally, I will propose some practical steps that would improve the effectiveness of next-gen sequencing diagnosis of neurodegenerative disorders and present my view of the near future based on the technologies that are available or will soon become available.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...
    Show Resources